Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation
Company Announcement Nanoform Finland Plc November 22, 2023 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation Project Blockbuster is progressing well. The clinical manufacture of nanoformed material for the project has been done and our partner has successfully made tablets. The clinical trials are expected to start before year end and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial